Ismael Samudio
About Ismael Samudio
Ismael Samudio serves as the Senior Director of Cancer Biology & Translational Sciences at Notch Therapeutics and is the Founder and Chief Scientific Officer at Immunity Diagnostics Inc. He has a Ph.D. in Genetics from Texas A&M University and has extensive experience in cancer research and immunotherapy.
Current Role at Notch Therapeutics
Ismael Samudio serves as the Senior Director of Cancer Biology & Translational Sciences at Notch Therapeutics. He has held this position since 2021, contributing to advancements in cancer immunotherapy through innovative applications of synthetic biology. His role involves overseeing research initiatives and developing therapeutic strategies aimed at improving patient outcomes in oncology.
Previous Experience at BC Cancer Agency
Prior to his current role, Ismael Samudio worked as a Research Associate at BC Cancer Agency from 2013 to 2015. During his time there, he engaged in research focused on cancer biology, contributing to the understanding of cancer mechanisms and potential therapeutic targets.
Educational Background in Genetics and Biochemistry
Ismael Samudio earned his Doctor of Philosophy (Ph.D.) in Genetics from Texas A&M University, where he studied from 1997 to 2002. He also holds a Bachelor of Science (B.S.) in Biochemistry and Genetics from the same institution, completed between 1991 and 1994. His educational background provides a strong foundation for his work in cancer biology and immunotherapy.
Founding Role at Immunity Diagnostics Inc.
In addition to his position at Notch Therapeutics, Ismael Samudio is the Founder and Chief Scientific Officer (CSO) of Immunity Diagnostics Inc., a role he has held since 2020. His leadership at the company focuses on developing diagnostic tools and therapeutic strategies in the field of immunology.
Multidisciplinary Expertise in Cancer Research
Ismael Samudio possesses a multidisciplinary background that includes expertise in biochemistry, metabolism, and cellular biology. This diverse knowledge base informs his approach to immunology, particularly in the context of de-risking immunotherapeutic concepts to create effective cancer treatment strategies.